samedan logo
 
 
spacer
home > pmps > spring 2003 > current good manufacturing practice for biological apis
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Current Good Manufacturing Practice for Biological APIs

Biological manufacturing is currently in the spotlight for several reasons. The pipeline of new pharmaceuticals is reported to contain nearly 1,000 biotechnology based products(1) whilst biotechnology-based products constitute then about 30 per cent of the total pharmaceutical pipeline. The expectations of biotechnology products are growing as they enter late stage clinical phases.

Over recent years, the average number of approved biotechnology-based drugs has been around 30 per year. The increase in approved products has, for monoclonal antibodies (MAb) and other recombinant proteins produced by mammalian cell culture, led to a production capacity shortage being reported by several consultants. Microbially derived products donÕt seem as affected, but manufacturing using microbial systems requires as much planning and preparation, even if capacity shortage is not obvious.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Liselotte Larsson PhD, Marketing and Sales at Novozymes Biopharma AB

Liselotte Larsson PhD has been responsible for marketing and sales at Novozymes Biopharma AB and its predecessors since 1996.

Prior to her employment with Novozymes Biopharma, Dr Larsson worked for The Swedish Technical AttachŽs and for the Swedish environmental authorities. Dr Larsson gained her PhD in Biotechnology at Lund University, Sweden and became involved with marketing after joining the company.

spacer
Liselotte Larsson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bio-Rad Launches Its CFX Opus Dx Real-Time PCR Detection Systems for In Vitro Diagnostics

HERCULES, Calif.–October 21, 2021–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the CFX™ Opus 96 Dx System and the CFX™ Opus 384 Dx System
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement